Lucane Pharma SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Lucane Pharma SA - overview
Established
2009
Location
Paris, -, France
Primary Industry
Pharmaceuticals
About
Founded in 2009 and based in Paris, France, Lucane Pharma SA develops pharmaceutical products. In October 2017, Eurocept Groep acquired Lucane Pharma SA. The company develops, co-develops, supplies, and distributes pharmaceutical products such as GranuPAS, used for the treatment of urea cycle disorders; Pheburane, for multi-drug resistant tuberculosis; and Ucedane, for hyperammonaemia. The firm generates revenue from supplying and distributing its pharmaceutical products.
The company is currently engaged in the development of 9 pharmaceutical products.
Current Investors
Eurocept Groep
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.lucanepharma.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Lucane Pharma SA - timeline of key events
Lucane Pharma SA - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 5,080,423.9 | 5,877,267.3 | 5,696,122.4 | 8,618,503.5 | 9,629,005 | - | - | - |
| % Revenue Growth (YoY) | - | 15.7% | (3.1%) | 51.3% | 11.7% | - | - | - |
| EBITDA (USD) | (1,477,265.6) | 146,468.7 | 588,150.4 | 2,300,950 | 1,109,520 | - | - | - |
| Operating Income (USD) | (1,477,265.6) | 95,852.6 | 537,611 | 2,270,948.3 | 1,086,950 | - | - | - |
| Operating Margin | (29.1%) | 1.6% | 9.4% | 26.3% | 11.3% | - | - | - |
| % EBITDA Margin | (29.1%) | 2.5% | 10.3% | 26.7% | 11.5% | - | - | - |
| NET Income (USD) | (1,478,682.6) | 105,788.9 | 439,116.2 | 2,034,196.6 | 1,703,384 | - | - | - |
| % Net Margin | (29.1%) | 1.8% | 7.7% | 23.6% | 17.7% | - | - | - |
Lucane Pharma SA - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Lucane Pharma SA | - |
Displaying 1 - 1 of 1
Lucane Pharma SA - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.